AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

I. LISTING OF CLAIMS:

1-32. (cancelled)

33. (currently amended) An expression vector,

~~which comprises~~comprising: (a) a first coding region encoding ~~PPIase~~a peptidyl-prolyl cis-trans isomerase (PPIase) having molecular chaperone activity, and

(b) a region having at least one restriction enzyme site in which a second coding region encoding a desired protein can be inserted.

34. (previously presented): The expression vector according to claim 33,

wherein the first coding region is operatively linked to a promoter, and the restriction enzyme site is in the same reading frame as the first coding region, and is downstream of the first coding region.

35. (currently amended): The expression vector according to claim 33 ,

which has a region ~~being~~ between ~~a~~the first coding region and ~~a~~the region having at least one restriction enzyme site in which a second coding region can be inserted, ~~and is translated in the same reading frame to be a protease digestion site~~encoding a protease digestion site in the same reading frame as the first and second coding regions.

36. (previously presented): An expression vector,

wherein a second coding region encoding a desired protein is inserted into the expression vector according to claim 33.

37. (previously presented): The expression vector according to claim 33 ,

wherein the PPIase having molecular chaperone activity is FKBP-type PPIase.

38. (previously presented): The expression vector according to claim 33, wherein the PPIase having molecular chaperone activity is cyclophilin-type PPIase.

39. (previously presented): The expression vector according to claim 33, wherein the PPIase having molecular chaperone activity is parvulin-type PPIase.

40. (previously presented): The expression vector according to claim 37, wherein the FKBP-type PPIase is archaebacterial FKBP-type PPIase.

41. (previously presented) The expression vector according to claim 40, wherein the archaebacterial FKBP-type PPIase is short type FKBP-type PPIase.

42. (previously presented): The expression vector according to claim 33, wherein the PPIase having molecular chaperone activity comprises an IF domain and/or a C-terminal domain of archaebacterial FKBP-type PPIase.

43. (previously presented): The expression vector according to claim 37, wherein the FKBP-type PPIase is trigger factor-type PPIase.

44. (previously presented): The expression vector according to claim 33, wherein the PPIase having molecular chaperone activity comprises a N-terminal domain and/or a C-terminal domain of trigger factor-type PPIase.

45. (previously presented): The expression vector according to claim 37, wherein the FKBP-type PPIase is FkpA-type PPIase.

46. (previously presented): The expression vector according to claim 33, wherein the PPIase having molecular chaperone activity comprises a N-terminal domain of FkpA-type PPIase.

47. (previously presented): The expression vector according to claim 37, wherein the FKBP-type PPIase is FKBP52-type PPIase.

48. (previously presented): The expression vector according to claim 33, wherein the PPIase having molecular chaperone activity comprises a C-terminal domain of FKBP52-type PPIase.

49. (previously presented): The expression vector according to claim 38, wherein the cyclophilin-type PPIase is CyP40-type PPIase.

50. (previously presented): The expression vector according to claim 33, wherein the PPIase having molecular chaperone activity comprises a C-terminal domain of CyP40-type PPIase.

51. (previously presented): The expression vector according to claim 39, wherein the parvulin-type PPIase is SurA-type PPIase.

52. (previously presented): The expression vector according to claim 33, wherein the PPIase having molecular chaperone activity comprises a N-terminal domain of SurA-type PPIase.

53. (previously presented): The expression vector according to claim 36, wherein the second coding region has a nucleotide sequence encoding a monoclonal antibody.

54. (previously presented): The expression vector according to claim 36, wherein the second coding region has a nucleotide sequence encoding a membrane protein.

55. (previously presented): A host, which contains the expression vector according to claim 33.

56. (previously presented): The host according to claim 55,

which is Escherichia coli.

57. (previously presented) A fused protein,

which comprises PPIase having molecular chaperone activity and a desired protein.

58. (previously presented): The fused protein according to claim 57,

which comprises a protease digestion site between PPIase having molecular chaperone activity and a desired protein.

59. (currently amended): A process for producing a fused protein comprising PPIase having molecular chaperone activity and a desired protein,

~~which comprises making the expression vector according to claim 36,~~ comprising culturing a host cell transformed with the expression vector of claim 33 to express the fused protein.

60. (currently amended): The process for producing a fused protein according to claim 59,

which comprises culturing ~~the~~a host containing the expression vector under condition of expression of the expression vector, and ~~making express~~ expressing the fused protein in a cytoplasm.

61. (currently amended): The process for producing a fused protein according to claim 59,

which comprises providing a region being transcribed and translated to be a signal sequence at a 5' terminus of ~~a~~the first coding region or a ~~5'~~ 3' terminus of ~~a~~ the second coding region of the expression vector, and culturing a host containing the expression

vector under condition of expression of the expression vector to express the fused protein in athe periplasm or a medium.

62. (currently amended): The process for producing a fused protein according to claim 59,

which comprises ~~making the expression vector~~culturing a host cell transformed with the expression vector to express the fused protein in a cell-free translation system.

63. (currently amended): The process for producing a fused protein according to claim 59,

wherein the fused protein is adsorbed on a carrier harboring macrolide, cyclosporin, juglone, or ~~its analogous~~ a compound ~~inhibiting~~ which inhibits PPIase activity, ~~and then the~~ wherein said carrier is recovered and the fused protein is recovered from the carrier.

64. (currently amended): A process for producing a desired protein,

which comprises digesting the fused protein comprising athe protease digestion site obtained by the process according to claim 59, with a protease digesting a protease digestion site.